Literature DB >> 20508558

[Radiofrequency ablation for palliation of soft tissue tumor pain].

R Sanou1, C Bazin, I Krakowski, H Boccaccini, J Mathias, S Beot, F Marchal, D Regent.   

Abstract

PURPOSE: To assess the efficacy of radiofrequency (RF) ablation for palliation of soft tissue tumor pain.
MATERIALS AND METHODS: Retrospective study of 12 patients receiving palliative treatment for soft tissue tumors (5 primary tumors including 4 sarcomas and 1 PEComa and 7 metastatic tumors) with pain refractory to standard management. RF ablation was performed under CT or ultrasound guidance.
RESULTS: The efficacy was determined by using pain scores and treatment regimen modifications after RF ablation. Response was graded as absent, partial or complete. Short term symptomatic relief was observed in 100% of cases, with complete response in 43% of cases ; Mid term and long term symptomatic relief was observed in 70% and 83% of cases respectively. We also observed dosage reduction for narcotics with corresponding reduction in related side-effects and functional improvement in some patients. A single case of complication with serosanguinous collection within a region of necrosis was observed.
CONCLUSION: Radiofrequency ablation for palliation of soft tissue tumor pain may be a useful complement to standard management. It results in symptomatic improvement with few complications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20508558     DOI: 10.1016/s0221-0363(10)70039-1

Source DB:  PubMed          Journal:  J Radiol        ISSN: 0221-0363


  2 in total

1.  Soft-tissue cryoablation in diffuse locations: feasibility and intermediate term outcomes.

Authors:  Peter J Littrup; Hyun J Bang; Brandt P Currier; Dylan J Goodrich; Hussein D Aoun; Lance K Heilbrun; Barbara A Adam
Journal:  J Vasc Interv Radiol       Date:  2013-09-20       Impact factor: 3.464

2.  Computed tomography-guided radiofrequency ablation for palliation of a painful supraclavicular soft-tissue metastasis invading the brachial plexus.

Authors:  Aristotelis Kechagias; Spiros Delis; Christos Dervenis; Petros Maniatis; John Papailiou
Journal:  Oncol Lett       Date:  2013-09-12       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.